A case of Anti‐MDA5‐Positive dermatomyositis after inactivated COVID‐19 vaccine
- 31 October 2022
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (2) , E127-E129
Abstract
No abstract availableFunding Information
- Data Center of Management Science, National Natural Science Foundation of China - Peking University (81303139, 82103726)
This publication has 9 references indexed in Scilit:
- Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based reviewRheumatology International, 2022
- Immunogenicity of COVID‐19 vaccines in patients with diverse health conditions: A comprehensive systematic reviewJournal of Medical Virology, 2022
- COVID-19 vaccine-associated dermatomyositisJAAD Case Reports, 2022
- Dermatomyositis Following BNT162b2 mRNA COVID-19 VaccinationJournal of Korean Medical Science, 2022
- Presence of Anti-MDA5 Antibody and Its Value for the Clinical Assessment in Patients With COVID-19: A Retrospective Cohort StudyFrontiers in Immunology, 2021
- A RAPIDLY PROGRESSIVE AND RARE ILLNESS: AUTOANTIBODIES AGAINST MELANOMA DIFFERENTIATION-ASSOCIATED PROTEIN 5 (ANTI-MDA5): AMYOPATHIC DERMATOMYOSITIS WITH PROGRESSIVE INTERSTITIAL LUNG DISEASE THAT DEVELOPED AFTER COVID-19 VACCINEChest, 2021
- Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung diseaseRheumatology, 2020
- Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositisAnnals of the Rheumatic Diseases, 2020
- 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsAnnals of the Rheumatic Diseases, 2017